The deal provides Spero with a clinically validated pathway (CD40L) and a clear Phase 2 catalyst in Q2 2027, but the stock may re-rate on execution risk and financing needs. Monitor for any equity or debt offering to fund development, and watch for Innovent's Phase 2 SjD data in early 2027 as a read-through for the mechanism.
Drug in focus
SPRO drug pipeline →SP001
◆ Mixed Named in this press release- Impact
- Phase
- Phase 2-ready (Phase 1 completed in healthy volunteers and Sjögren's disease)
- Time to market
- 5+ years (Phase 2 starting Q2 2027; IgG4-RD is an orphan indication but still requires Phase 2 and Phase 3)
- Next catalyst
- None dated
What to watchSP001 is a new pipeline asset for Spero, announced alongside a $105M non-dilutive royalty financing from Utebzi sales. Watch for the Phase 2 initiation in IgG4-RD (Q2 2027) as the next catalyst. The stock may re-rate on execution towards Phase 2 start, but the $1.1B milestone burden relative to Spero's ~$126M market cap is a significant overhang. Monitor Innovent's Phase 2 SjD data in China (early 2027) as a read-through for the mechanism.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 14 $1.70entry
- T+1 · 4mo ago 0.00%α −0.40% · $1.70
- T+5 · 4mo ago −15.29%α −14.00% · $1.44
- T+20 · 3mo ago −27.65%α −30.14% · $1.23
- T+60 · 6w ago −31.18%α −34.55% · $1.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spero Therapeutics in-licensed global rights (ex-China) to SP001 (IBI355), a third-generation anti-CD40L antibody, from Innovent Biologics. The deal includes up to ~$1.1B in total milestones plus tiered royalties, and Spero plans a Phase 2 trial in IgG4-RD starting Q2 2027. This transaction transforms Spero's pipeline from infectious disease into immunology, but the asset is preclinical for Spero's lead indication and carries significant development risk.
Key Financial Metrics
Key Facts
- Spero receives exclusive global rights (ex-Greater China) to SP001 (IBI355), a third-generation Fc-silent anti-CD40L antibody.
- Total deal value up to ~$1.1B in development, regulatory, and commercial milestones plus tiered royalties on net sales.
- Spero plans to initiate a Phase 2 trial in IgG4-RD in Q2 2027; Innovent plans a Phase 2 in Sjögren's disease in China by early 2027.
- SP001 has completed Phase 1 SAD/MAD healthy volunteer studies and a Phase 1b MAD study in SjD (data presented at EULAR 2026).
- Spero is a clinical-stage biopharma with ~$126M market cap; this in-licensing establishes a new immunology pipeline.
Financial Impact
Up to ~$1.1 billion in milestone payments plus tiered royalties; no upfront payment amount disclosed.
Risk Factors
- SP001 is still preclinical for IgG4-RD; Phase 2 may fail or be delayed.
- Spero's small market cap (~$126M) may require dilutive financing to fund development.
- Competition from other anti-CD40L antibodies (e.g., amlitelimab, dapirolizumab) could limit commercial potential.
- Milestone payments to Innovent create a significant financial obligation if development succeeds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326657 |
Track record
17 reports on SPRO
4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
- Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
- Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
- Jul 14, 202617w ago Press Release Bullish 7/10 Viewing Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers